44 / 88
HIPERTENSIÓN / 2015 / VOL. 20
42
La albúmina en la orina es muy estable a temperaturas normales, de modo que las muestras
de orina no necesitan ser congeladas al ser enviadas a otros laboratorios; ni el proceso de
almacenamiento ni el tiempo incrementan las variaciones de las técnicas actuales. Por lo
tanto, la MAU puede ser fácilmente medida en la mayoría de los pacientes hipertensos.
Conclusiones
MAU es un marcador de riesgo CV en pacientes con HTA asociada a: diabetes mellitus,
síndrome metabólico y/o hipertrofia ventricular izquierda
(4)
.
La presencia de MAU en un hipertenso sugiere fuertemente que se trata de un paciente non-
dipper y sal sensible
(5)
.
Bibliografía
1. Montanes Bermudez R, Gracia Garcia S, Perez Surribas D, Martinez Castelao A, Bover Sanjuan J. Consensus Document. Recommendations on assessing
proteinuria during the diagnosis and follow-up of chronic kidney disease. Nefrologia. 2011;31(3):331-45.
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1-266.
3. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from
Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67(6):2089-100.
4. Stephen R, Jolly SE, Nally JV, Jr., Navaneethan SD. Albuminuria: when urine predicts kidney and cardiovascular disease. Cleve Clin J Med. 2014;81(1):41-50.
5. Tagle R, Gonzalez F, Acevedo M. [Microalbuminuria and urinary albumin excretion in clinical practice]. Rev Med Chil. 2012;140(6):797-805.
6. Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep. 2010;12(5):364-8.
7. Palatini P, Mormino P, Dorigatti F, Santonastaso M, Mos L, De Toni R, et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage
1 hypertension: the HARVEST. Kidney Int. 2006;70(3):578-84.
8. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney
Dis. 1999;34(6):973-95.
9. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic
and nondiabetic individuals. JAMA. 2001;286(4):421-6.
10. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia. 2008;51(5):714-25.
11. Haraldsson B, Nyström J, Deen WM. Properties of the Glomerular Barrier and Mechanisms of Proteinuria. Physiological Reviews. 2008;88(2):451-87.
12. Pedrinelli R, Penno G, Dell'Omo G, Bandinelli S, Giorgi D, Di Bello V, et al. Microalbuminuria and transcapillary albumin leakage in essential hypertension.
Hypertension. 1999;34(3):491-5.
13. Cerasola G, Cottone S, Mule G. The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor.
J Hypertens. 2010;28(12):2357-69.
14. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens. 1996;14(2):223-8.
15. Pontremoli R, Viazzi F, Sofia A, Tomolillo C, Ruello N, Bezante GP, et al. Microalbuminuria: a marker of cardiovascular risk and organ damage in essential
hypertension. Kidney Int Suppl. 1997;63:S163-5.
16. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task
Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J
Hypertens. 2007;25(6):1105-87.
17. Hogan D, Lurbe E, Salabat MR, Redon J, Batlle D. Circadian changes in blood pressure and their relationships to the development of microalbuminuria in
type 1 diabetic patients. Curr Diab Rep. 2002;2(6):539-44.
18. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcome on treatment with
losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens. 2004;22(9):1805-11.
19. Pedrinelli R, Dell'Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J
Hum Hypertens. 2002;16(2):79-89.
20. Tagle R, Acevedo M, Vidt DG. Microalbuminuria: is it a valid predictor of cardiovascular risk? Cleve Clin J Med. 2003;70(3):255-61.
21. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of
cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol.
1999;19(3):617-24.
22. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease.
Arterioscler Thromb Vasc Biol. 1999;19(8):1992-7.
23. Wachtell K, Olsen MH, Dahlof B, Devereux RB, Kjeldsen SE, Nieminen MS, et al. Microalbuminuria in hypertensive patients with electrocardiographic left
ventricular hypertrophy: the LIFE study. J Hypertens. 2002;20(3):405-12.
24. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, et al. Albuminuria predicts cardiovascular events independently of left ventricular mass in
hypertension: a LIFE substudy. J Hum Hypertens. 2004;18(6):453-9.
25. Schrader J, Luders S, Kulschewski A, Hammersen F, Zuchner C, Venneklaas U, et al. Microalbuminuria and tubular proteinuria as risk predictors of
cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*. J Hypertens. 2006;24(3):541-8.
26. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular
events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005;45(2):198-202.
27. Asselbergs FW, Diercks GFH, Hillege HL, van Boven AJ, Janssen WMT, Voors AA, et al. Effects of Fosinopril and Pravastatin on Cardiovascular Events in
Subjects With Microalbuminuria. Circulation. 2004;110(18):2809-16.